Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

AHT begins equine herpes virus vaccine research
Equine herpes virus causes respiratory disease, abortion or fatal illness in newborn foals.
Charity to design a modified live virus vaccine 

The Animal Health Trust (AHT) has begun research into developing a new vaccine to protect against equine herpes virus (EHV-1).

Overseen by Dr Neil Bryant, the research comes after the AHT became aware of a pressing need for progress towards a new and improved EHV-1 vaccine.

In March, the Newmarket-based charity was called upon to work with the racing industry and affected parties in dealing with confirmed cases of EHV-1 abortion in Yorkshire and Suffolk. This need led to the development of an Equine Industries EHV Vaccine Steering Group, comprising of world-renowned experts on both human and equine herpes virus.

Chaired by Professor Joe Brownlie of the RVC, the steering group has looked at the existing scientific evidence and agreed the most appropriate way forward is for the AHT to design a modified live virus (MLV) vaccine.

“We’re at the beginning of a very exciting and potentially ground-breaking vaccine development,” said Dr Bryant. “Through our research, we will construct different viruses with attenuating mutations and assess their suitability as MLVs.

“We hope our findings will enable further development by vaccine manufacturers in creating an effective vaccine to protect against the serious clinical signs induced by EHV-1.”

EHV-1 causes respiratory disease, abortion or fatal illness in newborn foals. It also causes neurological disease in adult horses.

Whilst EHV can have severe consequences, there is no vaccine that is licensed to protect against the neurological form of the disease. Existing vaccines do not offer sufficient protection - something that was emphasised in 2016 by the Hertfordshire ‘abortion storm’ in fully vaccinated animals.

“EHV is a major welfare concern for horses and foals and causes emotional, as well as financial strains, on horse owners and breeders around the world,” said Dr Bryant. “It can strike any horse at any time so a vaccine will be of global welfare benefit to all horses, including the Thoroughbred and sports horse breeding industries, and would help control this serious and sometimes fatal disease.”

Become a member or log in to add this story to your CPD history

Animal Medicines Amnesty returns this November

News Story 1
 Veterinary practices are being urged to help owners safely dispose of any unused and expired pet medicines - not just antibiotics - during November's Animal Medicines Amnesty.

Organised by the Responsible Use of Medicines Alliance Companion Animal and Equine (RUMA CA&E), the initative is supported by a range of cross-sector organisations.

Practices are encouraged to use the campaign to engage the whole practice team and raise awareness of the safe disposal of medicines with clients. Learn how your practice can get involved at rumacae.org.uk 

Click here for more...
News Shorts
APHA launches free virtual work experience programme

The Animal and Plant Health Agency (APHA), in collaboration with Springpod, has launched a free virtual work experience programme, giving young people across the UK the chance to explore careers dedicated to protecting animal and plant health.

The on-demand programme offers a unique insight into career opportunities within APHA, showcasing how students can contribute to tackling some of the UK's most critical biosecurity and environmental challenges.

Designed for students aged 13 and over, the course includes more than 10 hours of engaging content featuring real-life industry insights, scenario-based challenges, and practical guidance on applying for jobs. To register for the course, visit the APHA website.